Alonso Torres AM, Arevalo Bernabe AG, Becerril Rios N, Hellin Gil MF, Martinez Sesmero JM, Meca Lallana V, Ramio-Torrenta L, Rodriguez-Antiguedad A, Gomez Maldonado L, Triana Junco I, Gomez-Barrera M, Espinoza Camac N, Oyaguez I. Cost-Analysis of Subcutaneous vs Intravenous Administration of Natalizumab Based on Patient Care Pathway in Multiple Sclerosis in Spain. Pharmacoecon Open. 2023 May;7(3):431-441. doi: 10.1007/s41669-023-00394-2. Epub 2023 Feb 21. PubMed PMID: 36802327; PubMed Central PMCID: PMC10169937.
AÑO: 2023